Canopy Growth Corp.: Is This Stock Worth a Shot?

Canopy Growth Corp. (TSX:WEED) offers big potential long-term gains, but there are near-term risks.

| More on:

Marijuana stocks continue to attract significant investor attention, especially after the strong pullback since February.

Let’s take a look at Canopy Growth Corp. (TSX:WEED) to see if it deserves to be in your portfolio right now.

Focused growth

Canopy is doing all the right things as it consolidates its position as a market leader in the growing medical marijuana market and positions itself for the opening of a recreational market, potentially next year.

Management has made a series of key acquisitions, including the purchase of Mettrum Health, which provided a nice boost to the company’s list of registered medical marijuana patients, added new national brands, and brought important production facilities into the fold.

Production growth is a core part of Canopy’s strategy as it prepares for the opening of a Canadian recreational market pegged at a value of at least $5 billion per year.

In order to scale up quickly and do so in a cost-efficient way, Canopy has partnered with a real estate company, the Goldman Group. Under the agreement, Goldman will build or acquire properties and outfit them to meet Canopy’s production requirements.

Canopy will then lease the facilities from Goldman.

In addition, Canopy purchased the property that houses its head office as well as the surrounding land. The building has enough space to nearly triple production, and the 42 acres of land offers expansion opportunities.

On the sales side, the company just reported fiscal Q1 2018 revenue of $15.9 million, representing a 127% increase over the same period last year.

Canopy set up a new online sales platform this spring to provide patients with a single location to access all of the company’s brands as well as offer other producers an option to get their product to market.

International markets will be served by a new global brand that will initially focus on Germany and Chile.

Overall, the company is doing a great job as it solidifies its leadership position in the medical marijuana market.

What about the recreational market?

Canopy’s market capitalization at the time of writing is $1.55 billion, which is a lot for a company with quarterly revenue of $16 million and a net loss of $4.4 million.

So, investors are betting on the recreational market that is supposed to open next summer.

The Federal Government maintains its optimism that Canadians will be able to legally purchase marijuana by July 1 next year, but several provinces are already asking for Ottawa to extend the timeline.

At this point, I’d be careful betting on a summer 2018 launch.

The provinces are burdened with all of the difficult decisions, including setting prices, determining sales outlets, and figuring out how to oversee the market in their own backyards.

Given the significant political risks of a botched rollout, it wouldn’t be a surprise to see the whole thing get delayed for another year or two as the provinces try to get their ducks in order. As such, there is a risk that a significant pushback of the launch could hit marijuana stocks, including Canopy.

Should you buy now?

This company is poised to do well once the recreational market is finally up and running, and it could very quickly grow into its valuation.

If you think the recreation market will arrive on schedule, it might be worthwhile to start a position in Canopy, but I would keep the investment small right now.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Andrew Walker has no position in any stock mentioned.

More on Investing

ETF chart stocks
Investing

Here Are My 2 Favourite ETFs for 2025

These are the ETFs I'll be eyeballing in the New Year.

Read more »

money goes up and down in balance
Dividend Stocks

This 6% Dividend Stock Is My Top Pick for Immediate Income

This Canadian stock has resilient business model, solid dividend payment and growth history, and a well-protected yield of over 6%.

Read more »

Canadian energy stocks are rising with oil prices
Energy Stocks

Outlook for Cenovus Energy Stock in 2025

A large-cap energy stock and TSX30 winner is a screaming buy for its bright business outlook and visible growth potential.

Read more »

TFSA (Tax-Free Savings Account) on wooden blocks and Canadian one hundred dollar bills.
Stock Market

CRA: Here’s the TFSA Contribution Limit for 2025

The TFSA is a tax-sheltered account that allows you to hold diversified asset classes at a low cost.

Read more »

Hourglass and stock price chart
Tech Stocks

1 Canadian Stock Ready to Surge Into 2025

There is a lot of uncertainty about the market in general as we move closer to the following year, but…

Read more »

think thought consider
Stock Market

Billionaires Are Selling Apple Stock and Picking up This TSX Stock Instead

Billionaires like Warren Buffett continue to trim stakes in Apple stock, with others picking up this long-term stock instead.

Read more »

ways to boost income
Dividend Stocks

1 Excellent TSX Dividend Stock, Down 25%, to Buy and Hold for the Long Term

Down 25% from all-time highs, Tourmaline Oil is a TSX dividend stock that offers you a tasty yield of 5%…

Read more »

canadian energy oil
Energy Stocks

Is Baytex Energy Stock a Good Buy?

Baytex just hit a 12-month low. Is the stock now oversold?

Read more »